International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis

Citation data:

Clinical Chemistry and Laboratory Medicine, ISSN: 1434-6621, Vol: 49, Issue: 8, Page: 1271-1274

Publication Year:
2011
Usage 1379
Abstract Views 837
Full Text Views 542
Captures 130
Exports-Saves 78
Readers 52
Social Media 1
Shares, Likes & Comments 1
Citations 106
Citation Indexes 106
Repository URL:
https://research-repository.uwa.edu.au/en/publications/a2735e56-9182-4cde-bdc5-dd057c3c2cfc; https://researchbank.acu.edu.au/fhs_pub/6877
PMID:
21605012
DOI:
10.1515/cclm.2011.602
Author(s):
Vasikaran, Samuel; Cooper, Cyrus; Eastell, Richard; Griesmacher, Andrea; Morris, Howard A.; Trenti, Tommaso; Kanis, John A.
Publisher(s):
Walter de Gruyter GmbH; Walter de Gruyter GmbH & Co. KG
Tags:
Biochemistry, Genetics and Molecular Biology; Medicine; bone mineral density; bone turnover markers; clinical risk factors; fracture risk; osteoporosis; reference standard; Endocrinology, Diabetes, and Metabolism
article description
The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group on Bone Marker Standards (WG-BMS) has evaluated the clinical potential of bone turnover markers (BTMs) in the prediction of fracture risk and for monitoring treatment. Research evidence suggests that BTMs may provide information on fracture risk independently from BMD, so that fracture risk prediction might be enhanced by their inclusion in assessment algorithms. The potential use of BTMs to predict the response to treatments for osteoporosis in the individual patient is also of great interest. Treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. However, there is still a need for stronger evidence on which to base practice in both situations. IOF/IFCC recommends one bone formation marker (serum procollagen type I N propeptide, s-PINP) and one bone resorption marker (serum C-terminal cross-linking telopeptide of type I collagen, s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to enlarge the international experience of the application of markers to clinical medicine and to help resolve uncertainties over their clinical use.